Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Urinary Bladder Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Leiomyosarcoma 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Mesothelioma, Malignant 1 Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Endometrioid 1

Interventions

enzalutamide 4 cabazitaxel 3 Docetaxel 3 Prednisone 2 talazoparib 1 rucaparib 1 pembrolizumab 1 olaparib 1 Zuclomiphene 1 XRP6258 1 Standard of Care 1 Radiosurgery 1 Positron Emission Tomography Computed Tomography 1 LY3023414 1 Injections 1 Carboplatin 1 Abituzumab 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostate Cancer Metastatic × rucaparib × Clear all

NCT03413995 2024-10-16

TRIUMPH

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed

12 enrolled 11 charts

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡